contractor articles (96)
Active Articles:
None to display.Retired Articles:
A48635: A55876: Implanted Fiducial Markers—Coding and Billing GuidelinesA48636: Administration of Certain Biological Reponse Modifiers
A48638: AJ1440: G-CSF (Filgrastim, Neupogen®)—Clarification on Correct Administration of Neupogen
A48639: AJ2357: Omalizumab (Xolair) administration and 96401-clarification of correct billing
A48640: AJ9025: VIDAZA and administration code 96401 - clarification of correct billing
A48645: COVERAGE FOR THREE-D RENDERING CPT CODES 76376 AND 76377
A48646: Descemet’s Stripping Endothelial Keratoplasty (DSAEK)—Coding and Billing
A48647: Electrocardiogram, 64 Leads or Greater—Coverage Guidelines
A48649: Information Update Regarding Payment and Coding for Drugs and
A48652: J2505: Clarification on correct administration of Neupogen and Neulasta
A48654: Medicare Part B Coverage of Drugs and Biologicals – Special Focus on the Unlabeled Use of Anti-Cancer Drugs
A48656: Medicare Payment for Uterine Artery Embolization
A48657: Prostate Specific Antigen Correct Coding: Use G0103 for Screening Exams
A48658: Requirements for the Payment of Medicare Claims - A Selection of Some Important Criteria
A48659: Screening and Noncovered Services
A48660: Screening Glaucoma Services
A48661: Skilled Nursing Facility Demand Bills
A48945: 0176T and 0177T: Transluminal dilation of aqueous outflow canal
A49018: Updated Medicare coverage for off-label use of anti-cancer drugs
A49164: Billing for drugs usually administered orally
A49166: Physician’s order for clinical laboratory services and diagnostic procedures
A49185: J9999/C9399: Plerixafor (MOZOBIL™) clarification of administration
A49261: 0197T/77499: Calypso® 4D localization system TM
A49263: A95805: Polysomnography and sleep testing extended date of accreditation
A49314: End-stage renal dialysis (ESRD) split-claim billing
A49474: Signature requirements clarification
A49606: Billing and coding information for prostate biopsies
A49768: Q0139 (TOB 72X) claims processing issue
A49812: Self-administered drug (SAD) list
A49972: Xiaflex™ (collagenase clostridium histolyticum) - coding instructions
A50943: Self-administered drug (SAD) list
A50978: Florida Part A inpatient prepayment review notification MS-DRG 470 (major joint replacement or reattachment of lower extremity)
A50989: Self-administered drug (SAD) list Part A: J1559
A51196: Florida Part A inpatient prepayment notification MS-DRG 460 (spinal fusion except cervical w/o MCC)
A51295: J3095: Vibativ (telavancin) clarification on billing
A51478: Inpatient prepayment review notification for MS-DRG 641 and MS-DRG 392
A51482: Self-administered drug (SAD) list Part A: J0630
A51721: Multiple local coverage determinations (LCDs) being retired
A51839: Medical nutrition therapy (MNT) national guidelines
A51853: Self-administered drug (SAD) list – Part A: C9399/J3490/J3590
A51987: Clarification of the proper use and billing of adenosine injections
A52072: Self-administered drug (SAD) list – Part A: J1744/J2212
A52213: Self-administered drug (SAD) list Part A: C9399/J3490/J3590
A52275: Noncovered services revision to the Part A LCD
A52307: Ocular photodynamic therapy (OPT) with verteporfin revision to the Part A LCD
A52309: Myocardial imaging positron emission tomography (PET) scan revision to the Part A LCD
A52320: Noncovered services revision to the Part A LCD
A52346: Noncovered services revision to the Part A LCD
A52357: Draft Sources of Information and Basis for Decision: Noncovered Services LCD
A52404: Draft - Sources of Information and Basis for Decision Noncovered Services LCD
A52553: Polysomnography and sleep testing revision to the Part A LCD
A52780: Self-administered drug (SAD) list Part A: J3590/C9399/Q3026
A52912: Botulinum toxins revision to the Part A LCD